Every dollar spent on immunization saves $6.30 in direct medical costs – a total savings of $10.5 billion. When including indirect costs such as lost days of work, disability,… [ Get More Details ]
Use of pneumonia vaccine in children reduced rates in adults age 65+
Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4;… [ Get More Details ]
Cost-effectiveness of flu vaccine
Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.
[ Get More Details ]
Effectiveness of pneumonia vaccine
PPSV23 (pneumococcal polysaccharide vaccine) protects against 23 types of pneumococcal bacteria and is 60% to 80% effective in preventing pneumococcal bacteremia in adults over the age of 65 who are… [ Get More Details ]